Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06016179 · ClinicalTrials.gov registry record · Phase 1
Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
A Phase 1 study of Malignant Pleural Effusion and Malignant Ascites, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06016179 is a Phase 1 study of Malignant Pleural Effusion and Malignant Ascites that is actively recruiting participants, run by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute). The registered enrollment target is 12 participants, below the 51-participant average among 3 other Malignant Pleural Effusion trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06016179, a Phase 1 study of Malignant Pleural Effusion and Malignant Ascites, is actively recruiting participants, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE). Patients will have a total of 4 doses, one dose administered each week. Each dose will be greater than the previous one.
Conditions Studied
Interventions
- DRUG Tocilizumab
Study Locations (1)
Pennsylvania
- Allegheny Health Network Cancer Institute - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-01-30 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
Sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)34 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06016179
The ClinicalTrials.gov registry entry for NCT06016179 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 51-participant average among 3 other Malignant Pleural Effusion trials with a reported enrollment target (76% lower). The listed sponsor is Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), which has 34 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Malignant Pleural Effusion appearing as the primary indexed condition, and to 1 intervention - of which Tocilizumab is the first listed.
NCT06016179 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06016179 about?
NCT06016179 is a clinical study titled "Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer". The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE). Patients will have a total of 4 doses, one dose administered each week. Each dose will be greater than the previo...
What is the current status of trial NCT06016179?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-01-30. Estimated completion is 2027-01.
What conditions does trial NCT06016179 study?
This clinical trial studies the following conditions: Malignant Pleural Effusion, Malignant Ascites.
What interventions are being tested in trial NCT06016179?
The interventions under investigation include: Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT06016179?
This trial is sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06016179 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Pleural Effusion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
RECRUITING · Phase 1
-
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
COMPLETED · Phase 1
-
UNC Pleural Fluid Registry
RECRUITING
-
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.